StockNews.AI
RPRX
StockNews.AI
222 days

Royalty Pharma Announces Dividend Increase

1. RPRX declares $0.22 dividend for Q1 2025, up 5% from last quarter. 2. Dividend payment scheduled for March 10, 2025, for eligible shareholders. 3. Company supports innovation through partnerships and royalty acquisitions. 4. RPRX's royalty portfolio includes over 35 commercial products. 5. Increases in dividends may attract more investors to RPRX shares.

4m saved
Insight
Article

FAQ

Why Bullish?

The dividend increase signals financial stability and growth potential, historically boosting share prices.

How important is it?

The dividend increase is a strong indicator of RPRX's financial health, affecting investment decisions.

Why Short Term?

Dividend announcements typically influence immediate investor sentiment and short-term stock performance.

Related Companies

VRTXGSKRHHBYJNJBIIBABBVPFENVS
January 09, 2025 16:15 ET  | Source: Royalty Pharma plc NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-6637ir@royaltypharma.com

Related News